Literature DB >> 21632286

Cytology, liquid-based cytology and automation.

John H F Smith1.   

Abstract

Quality-assured, comprehensive, cytology-based population screening programmes have resulted in a substantial decline in the incidence of, and mortality from, cervical cancer. Cytology classification systems divide squamous cell abnormalities into low grade and high grade. Women with high-grade squamous abnormalities, cytology suggestive of glandular neoplasia, or invasive disease are referred immediately for investigation. Previously, the optimal management of women with low-grade cytology was uncertain. The introduction of liquid-based cytology has improved specimen adequacy and laboratory productivity, and also provided the platform for human papillomavirus testing for triage of low-grade abnormality, follow up after treatment and, ultimately, primary screening with triage to cytology, particularly in HPV-vaccinated populations. Liquid-based cytology is also ideal for automation-assisted reading of cervical cytology samples; however, recent studies have reported that automation-assisted reading is less sensitive than manual reading and does not reduce the risk of cervical cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21632286     DOI: 10.1016/j.bpobgyn.2011.04.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  2 in total

1.  Clinical comparison of liquid-based and conventional cytology of oral brush biopsies: a randomized controlled trial.

Authors:  Constanze Olms; Nathalie Hix; Heinrich Neumann; Maryam Yahiaoui-Doktor; Torsten W Remmerbach
Journal:  Head Face Med       Date:  2018-05-29       Impact factor: 2.151

2.  Rehydration of Air-Dried Smears with Normal Saline: An Alternative for Conventional Wet Fixation Method in Cervical Cytological Study.

Authors:  Sachin Shivaji Kapse; Surekha U Arakeri; Divya P Yerranguntla
Journal:  J Cytol       Date:  2018 Oct-Dec       Impact factor: 1.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.